Harmless Bacteria Thrive in Patients with Inflammatory Bowel Disease
|
By LabMedica International staff writers Posted on 26 May 2015 |

Image: The CARY 50 BIO UV-Visible Spectrophotometer (Photo courtesy of Agilent Technologies).
The survival and proliferation of usually harmless Escherichia coli in the gut of inflammatory bowel disease patients may now be better understood, as fundamental mechanism through which the bacteria can thrive during flare-ups has been defined.
Some strains of E. coli normally live in the intestines of humans, and are important for a healthy digestive tract, but for people who suffer from inflammatory bowel diseases (IBD), these innocuous strains may proliferate during a flare-up and further contribute to disease and discomfort.
Scientists at Pennsylvania State University (University Park, PA, USA) and their colleagues studied the interactions between enterobactin, myeloperoxidase and lipocalin 2 and how they regulate E. coli in the intestine. Enterobactin (Ent) is an iron-loving chemical secreted by E. coli that takes iron from host proteins in the body and aids the proliferation of E. coli. Myeloperoxidase (MPO) is an antibacterial protein that white blood cells produce to fight bacteria, however Ent inhibits MPO from doing its job. Lipocalin 2 (Lcn2) is another protein, also produced by white blood cells, that gathers up Ent so that bacteria fail to obtain a sufficient amount of iron for their survival.
Spectral analysis of lactoperoxidase (LPO) during the oxidation of Ent, 2,3-dihydroxybenzoic acid (DHBA) and 4-aminobenzoic hydrazide (ABAH) was recorded at 412 nm using CARY50BIO UV-Visible Spectrophotometer (Agilent Technologies; Santa Clara, CA, USA). By using various techniques the team found that Lcn2 can counter the effects of Ent on MPO. They were able to define a new defense mechanism used by E. coli residing in a human or animal host, the inhibition of MPO by Ent. These findings define a fundamental mechanism by which E. coli surpasses the host innate immune responses during inflammatory gut diseases and gains a distinct survival advantage.
Matam Vijay-Kumar, PhD, an assistant professor of nutritional sciences and medicine and lead author of the study said, “Several types of inflammatory bowel disease are characterized by expansion of the opportunistic E. coli in the gut. However, the mechanisms by which E. coli can thwart the hostile host innate immune system are poorly understood. Identifying these mechanisms will help to reduce the E. coli burden in the inflamed gut and prevent chronic extra-intestinal diseases. We have to find a way to identify the drugs which can inhibit or degrade secreted enterobactin. Alternatively, since MPO is known to be pro-inflammatory not only in IBD but also in other inflammatory diseases, it may be possible to develop enterobactin-based drugs to alleviate inflammatory pathways.” The study was published on May 12, 2015, in the journal Nature Communications.
Related Links:
Pennsylvania State University
Agilent Technologies
Some strains of E. coli normally live in the intestines of humans, and are important for a healthy digestive tract, but for people who suffer from inflammatory bowel diseases (IBD), these innocuous strains may proliferate during a flare-up and further contribute to disease and discomfort.
Scientists at Pennsylvania State University (University Park, PA, USA) and their colleagues studied the interactions between enterobactin, myeloperoxidase and lipocalin 2 and how they regulate E. coli in the intestine. Enterobactin (Ent) is an iron-loving chemical secreted by E. coli that takes iron from host proteins in the body and aids the proliferation of E. coli. Myeloperoxidase (MPO) is an antibacterial protein that white blood cells produce to fight bacteria, however Ent inhibits MPO from doing its job. Lipocalin 2 (Lcn2) is another protein, also produced by white blood cells, that gathers up Ent so that bacteria fail to obtain a sufficient amount of iron for their survival.
Spectral analysis of lactoperoxidase (LPO) during the oxidation of Ent, 2,3-dihydroxybenzoic acid (DHBA) and 4-aminobenzoic hydrazide (ABAH) was recorded at 412 nm using CARY50BIO UV-Visible Spectrophotometer (Agilent Technologies; Santa Clara, CA, USA). By using various techniques the team found that Lcn2 can counter the effects of Ent on MPO. They were able to define a new defense mechanism used by E. coli residing in a human or animal host, the inhibition of MPO by Ent. These findings define a fundamental mechanism by which E. coli surpasses the host innate immune responses during inflammatory gut diseases and gains a distinct survival advantage.
Matam Vijay-Kumar, PhD, an assistant professor of nutritional sciences and medicine and lead author of the study said, “Several types of inflammatory bowel disease are characterized by expansion of the opportunistic E. coli in the gut. However, the mechanisms by which E. coli can thwart the hostile host innate immune system are poorly understood. Identifying these mechanisms will help to reduce the E. coli burden in the inflamed gut and prevent chronic extra-intestinal diseases. We have to find a way to identify the drugs which can inhibit or degrade secreted enterobactin. Alternatively, since MPO is known to be pro-inflammatory not only in IBD but also in other inflammatory diseases, it may be possible to develop enterobactin-based drugs to alleviate inflammatory pathways.” The study was published on May 12, 2015, in the journal Nature Communications.
Related Links:
Pennsylvania State University
Agilent Technologies
Latest Clinical Chem. News
- Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







